Quanta BioDesign is a research and manufacturing company committed to the development of a full range of discrete polyethylene glycol (dPEG®) PEGylation reagents for applications in diagnostics, therapeutics, peptide synthesis, oligonucleotide synthesis, and nanotechnology.
Quanta BioDesign’s vision incorporates a dedicated commitment to producing the most useful compounds for your current and future applications and needs using synthetic and process technology that allows the most economic incorporation of these products into your application.
dPEG® Based Chemical Modification Reagents
|
dPEG® Based Crosslinking Reagents
|
dPEG® Based Fluorescent and other Dye Labels
|
dPEG® Based Reagents for Peptide Modification
|
dPEG® Biotinylation Reagents
|
dPEG® Reagents for Nucleic Acids
|
Payload Delivery dPEG® Reagents
|
Premier Offering of NEW Crosslinkers & Probes with our Exclusive dPEG® spacers
|
Quanta BioDesign, Ltd. was founded for the purpose of developing and commercializing an extensive line of products for companies involved in drug discovery and diagnostic development programs. The company was founded in 1997 by Paul D. Davis, Ph.D. under the name BioOrganic Technologies, LLC. In the spring of 1999 the name was changed to Quanta BioDesign, Ltd., to better reflect the company’s mission. All of our products are based on our proprietary discrete polyethylene glycol (dPEG®) chemistries, including our processes for making these compounds. Our single molecular weight ethylene glycol conjugation technology, dPEG®, can eliminate common problems found in the development of diagnostic and therapeutic products, such as aggregation and non-specific interactions, poor water solubility, poor delivery, delivery issues/options, short serum half-life, toxicity and antigenicity. The dPEG® product line can be custom tailored to meet specific physical, chemical and morphological requirements in a broad array of diagnostic and therapeutic applications. Quanta BioDesign is involved in developing new cross-linking and labeling chemistries that incorporate the dPEG® technology, and will allow for new approaches in the area of therapeutic and diagnostic development.
The term “dPEG®” is Quanta BioDesigns trademarked acronym for “discrete poly(ethylene glycol)” or “discrete PEG”. Each of our products represents a single compound with a unique, specific, single molecular weight (MW) PEG synthesized de novo from pure, small units (e.g., triethylene glycol or tetraethylene glycol). In our numbering system, we name compounds as dPEG®nn, where nn stands for the number of oxygen atoms in the spacer unit. We do this in order to simplify the naming of the compounds. Our catalog has the exact structure of the single compound. Thus, for example, product number 10244, amino-dPEG®4-acid, has an amino group on one end, four (4) ethylene oxide units, and a carboxylic acid group on the other end, as shown below:
Some people prefer the term “monodisperse” to describe these PEG compounds. While not an inappropriate term, “monodisperse” implies either that